Janux Therapeutics Announces Pricing of Initial Public Offering streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors
Passage BioFebruary 19, 2021 GMT
PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system (CNS) disorders, today announced the appointment of Maxine Gowen, Ph.D., to its board of directors, effective Feb. 18. Dr. Gowen is chief executive officer of Tamuro Bio, a post that she has held since July 2019.
“We are immensely excited to have Maxine join our board of directors,” said Dr. Bruce Goldsmith, president and chief executive officer of Passage Bio. “Her public company leadership and deep clinical development expertise will provide tremendous support to Passage Bio as we transition to a clinical development organization in the first half of 2021.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of .
Passage BioFebruary 8, 2021 GMT
- Phase 1/2 trial expected to commence in first half of 2021
- Company has three INDs cleared for rare monogenic CNS disorders
PHILADELPHIA, Feb. 08, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for PBKR03, an adeno-associated virus (AAV)-delivery gene therapy being studied for the treatment of early infantile Krabbe disease (Globoid Cell Leukodystrophy). Currently, there are no approved disease-modifying therapies available for Krabbe disease, a rare lysosomal storage disease that most often
Passage Bio Announces Pricing of Public Offering forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host a series of virtual Research & Development events in 2021, with the first one scheduled for Monday, January 25, 2021, 11 a.m. to 1 p.m. ET.
The first event will focus on Passage Bio’s lead investigational therapy PBGM01 and its disease target, infantile GM1 gangliosidosis (GM1). Presenters for the event are:
Bruce Goldsmith, Ph.D., chief executive officer, who will present an overview of the Passage Bio pipeline and the GM1 disease and patient experience.